Therapeutic Classification: antipsoriatics
Pharmacologic Classification: interleukin antagonists, monoclonal antibodies
Absorption: 49% absorbed following SUBQ administration.
Distribution: Well distributed to tissues.
Metabolism/Excretion: Broken down by catabolic processes into peptides and amino acids.
Half-Life: 15–18 days
Contraindicated in:
- Hypersensitivity;
- Active, untreated infection.
Use Cautiously in:
- History of tuberculosis (TB) (possibility of reactivation);
- OB: Safety not established in pregnancy;
- Lactation: Use while breastfeeding only if potential maternal benefit justifies potential risk to infant;
- Pedi: Safety and effectiveness not established in children.
Exercise Extreme Caution in:
Plaque Psoriasis and Psoriatic Arthritis
- SC (Adults ): 100 mg initially and 4 wk later; then 100 mg every 8 wk.
Ulcerative Colitis
- IV SC (Adults ): Induction: 200 mg IV infusion initially; then 200 mg IV infusion 4 wk later (Wk 4); then 200 mg IV infusion 4 wk later (Wk 8); then continue with maintenance dosing. Maintenance: 100 mg SUBQ 8 wk after last induction IV dose (Wk 16); then 100 mg SUBQ every 8 wk OR 200 mg SUBQ 4 wk after last induction IV dose (Wk 12); then 200 mg SUBQ every 4 wk.
Crohn Disease
- IV SC (Adults ): Induction: 200 mg IV infusion initially; then 200 mg IV infusion 4 wk later (Wk 4); then 200 mg IV infusion 4 wk later (Wk 8) OR 400 mg SUBQ initially; then 400 mg SUBQ 4 wk later (Wk 4); then 400 mg SUBQ 4 wk later (Wk 8); then continue with maintenance dosing. Maintenance: 100 mg SUBQ 8 wk after last induction IV dose (Wk 16); then 100 mg SUBQ every 8 wk OR 200 mg SUBQ 4 wk after last induction IV dose (Wk 12); then 200 mg SUBQ every 4 wk.
